1_img1424895986.jpg 2_img1424896008.jpg 3_img1424896028.jpg 4_img1424896053.jpg
ГЛЕДФАРМ ЛТД intro pharmacovigilance logo-img
  • 1-img1423128723_img1424877095.jpg
  • 2-img1423128732_img1424877082.jpg
  • 3-img1423128813_img1424877070.jpg
  • 4-img1423128825_img1424877057.jpg
  • analiz111_img1422534233.jpg

ESZOL tablets


  •  vulvovaginal candidiasis;
  • pityriasis versicolor;
  •  dermatomycosis caused by pathogens sensitive to itraconazole (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), such as tinea pedis, tinea cruris, tinea corporis, tinea manus;
  •  oropharingeal candidiasis;
  • onychomycosis caused by dermatophytes and/or yeasts;
  • histoplasmosis;
  • systemic mycoses (in cases where first-line antifungal therapy cannot be applied or in case of inefficacy of treatment with other antifungal drugs that can be caused by existing pathology, insensitivity of the pathogen or drug toxicity):
  • aspergillosis and candidiasis;
  • cryptococcosis (including cryptococcal meningitis): treatment of immunocompromised patients with cryptococcosis and all patients with cryptococcosis of the central nervous system;
  • maintenance therapy in patients with AIDS in order to prevent recurrence of the existing fungal infection. 

Itraconazole should be administered for prophylaxis of fungal infections in patients with prolonged neutropenia in cases where standard therapy is insufficient.

1 tablet contains 100 mg of itraconazole; Antifungal agents for systemic use.

View instructions Dounload instruction
All Preparations